[1] Sangiovanni A,Prati GM,Fasani P,et al. The natural history of compensated cirrhosis due to hepatitis C virus:A 17-year cohort study of 214 patients. Hepatology,2006,43（6）:1303-1310.
[2] Peng CY,Chien RN,Liaw Y.F. Hepatitis B virus-related decompensated liver cirrhosis:Benefits of antiviral therapy. J Hepatol,2012,57（2）:442-450.
[3] Stanley MM,Ochi S,Lee KK,et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans administration cooperative study on treatment of alcoholic cirrhosis with ascites. N Engl J Med,1989,321（24）:1632-1638.
[4] Addolorato G,Leggio L,Ferrulli A,et al. Effectiveness and safety of Baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis:Randomised,double-blind controlled study. Lancet,2007,370（9603）:1915-1922.
[5] Mónica G,Baccaro ME,Torre A,et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis:A prospective study with time-dependent analysis. Am J Gastroenterol,2009,104（6）:1382-1389.
[6] Reynolds TB,Lieberman FL,Goodman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut,1978,19（6）:549-553.
[7] 顾锡炳,刘霞英,徐月琴. 不限钠饮食与限钠饮食对肝硬化患者肾血流量及腹水消退的影响. 中华消化杂志,2008,28（1）:61-62.
[8] Koretz RL,Avenell A,Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev,2012,16（5）:CD008344.
[9] Sorrentino P,Castaldo G,Tarantino L,et al. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing prepeated paracentesis. J Gastroenterol Hepatol,2012,27（4）:813-822.
[10] Santos J,Planas R,Pardo A,et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol,2003,39（2）:187-192.
[11] Angeli P,Fasolato S,Mazza E,et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:Results of an open randomised clinical trial. Gut, 2010,59（1）:98-104.
[12] Raza M,Qureshi U,Humayoun M,et al. Effect of intravenous mannitol in mobilization of resistant cirrhotic ascites. Eur J Gastroenterol Hepatol,2011,23（2）:184-188.
[13] Abecasis R, Guevara M,Miguez C,et al. Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. Scand J Gastroenterol,2001,36（3）:309-313.
[14] Marelli A,Bodini P,Reggiani A,et al. Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients. Minerva medica,1997,88（3）:109-115.
[15] Orman ES,Hayashi PH,Bataller R,et al. Paracentesis is associated with reduced mortality in patients hospitalized with cirrhosis and ascites. Clin Gastroenterol Hepatol,2014,12（3）: 496-503.
[16] Horie S,Nagai H,Yuuki T,et al. Effectiveness of recombinant human serum albumin in the treatment of ascites in liver cirrhosis:Evidence from animal model. Gen Pharmacol,1998, 31（5）:811-815.
[17] Nakamura T,Sata M,Suzuki K,et al. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial. Hepatol Res,2014,44（5）:502-514.
[18] Kasahara A, Kita K,Tomita E,et al. Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis:A multicenter clinical study. J Gastroenterol,2008,43（6）: 464-472.
[19] Guyader D,Patat A,Ellis-Grosse EJ,et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology,2002,36（5）:1197-1205.
[20] Dahl E,Gluud L,Kimer N,et al. Meta-analysis: The safety and efficacy of vaptans（tolvaptan,satavaptan and lixivaptan） in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther,2012,36（7）:619-626.
[21] Okita K,Sakaida I,Okada M,et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy,safety,and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol,2010,45（9）:979-987.
[22] Okita K,Kawazoe S,Hasebe C,et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema:A randomized,double-blind,placebo-controlled trial. Hepatol Res, 2014,44（1）:83-91.
[23] Sakaida I,Kawazoe S,Kajimura K,et al. Tolvaptan for improvement of hepatic edema:A phase 3,multicenter,randomized, double-blind,placebo-controlled trial. Hepatol Res,2014,44（1）:73-82.
[24] Watson H,Jepsen P,Wong F,et al. Satavaptan treatment for ascites in patients with cirrhosis:A meta-analysis of effect on hepatic encephalopathy development. Metab Brain Dis,2013, 28（2）:301-305.
[25] Krag A,Moller S,Henriksen J,et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology,2007,46（6）:1863-1871.
[26] Lata J,Marecek Z,Fejfar T,et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites-a randomized multicentric study. Hepatogastroenterology,2007,54（79）:1930.
[27] 李冬月,吴博,尹逊海,等. 特利加压素治疗失代偿期肝硬化疗效观察.实用肝脏病杂志,2012,15（1）:59-60.
[28] Yang YY,Lin HC,Lee WC,et al. One-week losartan administration increases sodium excretion in cirrhotic patients with and without ascites. J Gastroenterol,2002,37（3）:194-199.
[29] Sourianarayanane A,Barnes D,McCullough A. Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Gastroenterol Hepatol （NY）,2011,7（2）:132-134.
[30] Minakari M,Faiiaz L,Rowshandel M,et al. Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites. J Res Med Sci,2011,16（1）: 87-93.
[31] Kalambokis G,Fotopoulos A,Economou M,et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol,2007,46（2）:213-221.
[32] Singh V,Dhungana SP,Singh BR,et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. J Hepatol,2012,56（2）:348-354.
[33] Tandon P,Tsuyuki RT,Mitchell L,et al. The effect of 1 month of therapy with midodrine,octreotide-lar and albumin in refractory ascites:A pilot study. Liver Int,2009,29（2）:169-174.
[34] Bari K,Minano C,Shea M,et al. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol,2012,10（10）:1169-1175.
[35] Serste T,Melot C,Francoz C,et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology,2010,52（3）:1017-1022.
[36] Serste T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:A cross-over study. J Hepatol, 2011,55（4）:794-799.
[37] Krag A,Bendtsen F,Henriksen JH,et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut,2010,59（1）:105-110.
[38] Ge PS,Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol,2014,60（3）: 643-653.
[39] Huonker M,Schumacher YO,Ochs A,et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut,1999, 44（5）:743-748.
[40] Albillos A,Banares R,Gonzalez M,et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol,2005,43（6）:990-996.
[41] Chen RP,Zhu Ge XJ,Huang ZM,et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites:Metaregression and trial sequential meta-analysis. J Clin Gastroenterol,2014,48（3）:290-299.
[42] Salerno F,Camma C,Enea M,et al. Transjugular intrahepatic portosystemic shunt for refractory ascites:A meta-analysis of individual patient data. Gastroenterology,2007,133（3）:825-834.
[43] Deltenre P,Mathurin P,Dharancy S,et al. Transjugular intrahepatic portosystemic shunt in refractory ascites:A meta-analysis. Liver Int,2005,25（2）:349-356.
[44] Lai KN, Pun CO,Leung JW. Study of hepatic venous wedge and intraperitoneal pressures in cirrhotic patients with refractory ascites treated by dialytic ultrafiltration. J Gastroen Hepatol,1989,4（4）:325-330.
[45] Martin P,DiMartini A,Feng S,et al. Evaluation for liver transplantation in adults: 2013 Practice Guidelines:by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology,2014,59（3）:1144-1165. |
